Immune Bio selected for the Pitch Competition at G20 YEA
Immune Biosolutions has been selected to present its Edible Antibodies technology in the G20 Young Entrepreneurs Alliance Event in Fukuoka,…
-
-
New Research Collaboration with Janssen Biotech
Immune Biosolutions Enters into a Research Collaboration and License Agreement with Johnson & Johnson Innovation to Identify and Develop Therapeutic…
-
Immune Biosolutions Participating in Futurpreneur’s Growth Accelerator
After winning a pitch competition earlier this year, Immune Biosolutions’ founders are participating this week in the Futurpreneur’s Growth Accelerator…
-
CQDM to support a $1.1 million Immune Biosolutions’ research project.
CQDM to support a $1.1 million research and development project for Immune Biosolutions’ next-generation of anti-cancer treatment BOSTON, JUNE 6,…
-
Immune Biosolutions to Present at ICCS 2018
Immune Biosolutions has been selected to present at the 7th International Cancer Cluster Showcase 2018 in Boston during the BIO Convention…
-
Immune Biosolutions selected for JLABS @ Toronto
Immune Biosolutions selected for JLABS @ Toronto Immune Biosolutions is among the 22 growing businesses selected for JLABS @ Toronto….
-
Immune Biosolutions will continue its growth at EspaceLabz
Immune Biosolutions, a JLABS @ Toronto resident, is pleased to announce the relocation of its Sherbrooke headquarters and laboratories in…
-
G Protein-Coupled Receptors targeted by antibodies raised against three dimensional epitopes
Why target GPCRs with antibodies? The G Protein-coupled receptor (GPCR) superfamily represents the largest and single most important family of…
